Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

BHSTBIOHARVEST SCIENCES INC.

Nasdaq · CIK 0001723464
Filer category<br>Emerging growth company
Entity typeother
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts101

Identity from submissions API

NameBIOHARVEST SCIENCES INC.
CIK0001723464
TickersBHST
ExchangesNasdaq
Entity typeother
Category<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end1231
State of incorporationA1 British Columbia, Canada
Phone6046221186
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)0
Insider transactions (owner)0

Former names

  • CANNA-V-CELL SCIENCES INC. (2019-10-08T04:00:00.000Z → 2020-04-21T04:00:00.000Z)
  • Midnight Star Ventures Corp. (2017-11-24T05:00:00.000Z → 2018-10-15T04:00:00.000Z)
Business address
1140 - 625 HOWE STREET
VANCOUVER
A1
V6C 2T6
British Columbia, Canada
Mailing address
1140 - 625 HOWE STREET
VANCOUVER
A1
V6C 2T6
British Columbia, Canada

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

137 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-12 6-K REPORT 0001723464-26-000064 001-42389 261541795 34 544034
2026-10-29 6-K REPORT 0001723464-26-000062 001-42389 261502527 34 23261
2026-10-13 6-K REPORT 0001723464-26-000060 001-42389 261457451 34 34151
2026-10-08 6-K REPORT 0001723464-26-000058 001-42389 261449615 34 40286
2026-10-02 6-K REPORT 0001723464-26-000056 001-42389 261432837 34 26889
2026-09-15 6-K REPORT 0001723464-26-000054 001-42389 261381682 34 24851
2026-09-15 6-K REPORT 0001723464-26-000052 001-42389 261381657 34 26644
2026-09-14 6-K REPORT 0001723464-26-000050 001-42389 261378172 34 23993
2026-09-03 6-K REPORT 0001723464-26-000048 001-42389 261358078 34 28871
2026-08-12 6-K REPORT 0001723464-26-000046 001-42389 261264620 34 143258
2026-08-11 6-K REPORT 0001723464-26-000044 001-42389 261259812 34 538875
2026-07-29 6-K REPORT 0001723464-26-000042 001-42389 261217327 34 23201
2026-07-28 6-K REPORT 0001723464-26-000040 001-42389 261210623 34 23851
2026-07-16 6-K REPORT 0001723464-26-000038 001-42389 261178239 34 27016
2026-07-15 6-K REPORT 0001723464-26-000036 001-42389 261177291 34 28688
2026-06-18 6-K REPORT 0001723464-26-000034 001-42389 261102203 34 24772
2026-05-28 6-K REPORT 0001723464-26-000032 001-42389 261029924 34 2176361
2026-05-14 6-K REPORT 0001723464-26-000030 001-42389 26978484 34 140824
2026-05-14 6-K REPORT 0001723464-26-000028 001-42389 26977411 34 465135
2026-05-14 6-K REPORT 0001723464-26-000026 001-42389 26976469 34 41843
2026-05-13 6-K REPORT 0001723464-26-000024 001-42389 26972420 34 27437
2026-05-12 6-K REPORT 0001723464-26-000022 001-42389 26967742 34 31234
2026-05-11 6-K REPORT 0001723464-26-000020 001-42389 26964391 34 23425
2026-05-01 6-K REPORT 0001723464-26-000018 001-42389 26927916 34 20196
2026-04-29 6-K REPORT 0001723464-26-000016 001-42389 26913924 34 24405
2026-03-31 40-F BIOHARVEST SCIENCES INC. - FORM 40-F SEC FILING 0001376474-26-000257 001-42389 26821559 34 8229161 1 1
2026-03-27 6-K REPORT 0001723464-26-000014 001-42389 26805941 34 28260
2026-03-17 6-K REPORT 0001723464-26-000012 001-42389 26761431 34 23695
2026-03-16 6-K REPORT 0001723464-26-000010 001-42389 26755875 34 23115
2026-03-06 6-K REPORT 0001723464-26-000008 001-42389 26731360 34 21675
2026-03-05 6-K REPORT 0001723464-26-000006 001-42389 26725333 34 52306
2026-03-03 6-K REPORT 0001723464-26-000004 001-42389 26713225 34 22853
2026-01-07 6-K REPORT 0001723464-26-000002 001-42389 26515133 34 79818
2025-12-31 AW AMENDMENT WITHDRAWAL REQUEST FOR POS AM 0001723464-25-000035 333-289908 251617308 NE 5827
2025-12-29 POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 0001723464-25-000033 333-289908 251608874 33 284273
2025-12-18 6-K REPORT 0001723464-25-000031 001-42389 251583108 34 23174
2025-12-03 6-K REPORT 0001723464-25-000029 001-42389 251546018 34 173333
2025-11-13 6-K REPORT 0001723464-25-000027 001-42389 251478167 34 512118
2025-11-12 6-K REPORT 0001723464-25-000025 001-42389 251472254 34 22736
2025-11-10 6-K CURRENT REPORT 0001723464-25-000023 001-42389 251467518 34 25205
2025-11-10 6-K REPORT 0001723464-25-000021 001-42389 251463885 34 280333
2025-11-10 424B5 PROSPECTUS SUPPLEMENT 0001723464-25-000019 333-289908 251463768 33 445336
2025-11-06 424B7 PROSPECTUS SUPPLEMENT NO. 3 0001723464-25-000017 333-289908 251458997 33 446219
2025-11-04 6-K REPORT 0001723464-25-000015 001-42389 251448733 34 50188
2025-10-31 6-K REPORT 0001723464-25-000013 001-42389 251440847 34 95327
2025-10-31 6-K REPORT 0001723464-25-000011 001-42389 251439498 34 34302
2025-10-15 424B7 PROSPECTUS SUPPLEMENT NO. 2 0001723464-25-000009 333-289908 251395693 33 251035
2025-10-06 D xslFormDX01/primary_doc.xml 06b 0001723464-25-000007 021-559831 251375116 33 17032
2025-09-24 424B7 PROSPECTUS SUPPLEMENT NO. 1 0001139020-25-000337 333-289908 251338920 33 251752
2025-09-23 6-K REPORT 0001723464-25-000006 001-42389 251333500 34 27278
2025-09-22 6-K REPORT 0001723464-25-000004 001-42389 251329789 34 24475
2025-09-10 6-K REPORT 0001139020-25-000315 001-42389 251306144 34 25077
2025-09-09 6-K REPORT 0001139020-25-000304 001-42389 251302618 34 25362
2025-09-09 6-K REPORT 0001139020-25-000300 001-42389 251301077 34 40357
2025-09-08 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002876 333-289908 251301571 33 1928
2025-09-04 CORRESP filename1.htm 0001139020-25-000295 5589
2025-09-03 UPLOAD filename1.pdf 0000000000-25-009482 333-289908 40308
2025-09-02 6-K REPORT 0001139020-25-000289 001-42389 251284959 34 24123
2025-08-28 DEL AM DELAYING AMENDMENT 0001139020-25-000279 333-289908 251273576 33 6529
2025-08-28 F-3 REGISTRATION STATEMENT 0001139020-25-000277 333-289908 251269241 33 664810 1 1
2025-08-15 6-K REPORT 0001139020-25-000263 001-42389 251221592 34 21366
2025-08-13 6-K REPORT 0001139020-25-000255 001-42389 251213090 34 45683
2025-08-11 6-K REPORT 0001139020-25-000253 001-42389 251202497 34 102809
2025-08-11 6-K REPORT 0001139020-25-000251 001-42389 251201934 34 439447
2025-08-05 6-K REPORT 0001139020-25-000245 001-42389 251184332 34 49995
2025-07-23 6-K REPORT 0001139020-25-000239 001-42389 251142780 34 20900
2025-07-23 S-8 REGISTRATION STATEMENT 0001139020-25-000237 333-288882 251142398 33 268094
2025-07-07 6-K REPORT 0001139020-25-000203 001-42389 251108071 34 45654
2025-07-03 6-K REPORT 0001139020-25-000201 001-42389 251104143 34 36292
2025-06-10 6-K REPORT 0001139020-25-000164 001-42389 251035370 34 1507871
2025-06-04 6-K REPORT 0001139020-25-000158 001-42389 251022769 34 26102
2025-05-21 6-K REPORT 0001139020-25-000141 001-42389 25972787 34 25932
2025-05-15 6-K REPORT 0001139020-25-000128 001-42389 25954854 34 128360
2025-05-15 6-K REPORT 0001139020-25-000126 001-42389 25953907 34 454995
2025-05-12 6-K REPORT 0001139020-25-000113 001-42389 25935202 34 25473
2025-05-01 6-K REPORT 0001139020-25-000095 001-42389 25902297 34 25687
2025-04-01 6-K REPORT 0001139020-25-000019 001-42389 25797549 34 636038
2025-04-01 6-K REPORT 0001139020-25-000016 001-42389 25795863 34 141413
2025-03-31 F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING 0001376474-25-000301 001-42389 25794898 33 16533
2025-03-31 40-F BIOHARVEST SCIENCES INC. - FORM 40-F SEC FILING 0001376474-25-000299 001-42389 25794831 34 10038741 1 1
2025-03-17 6-K REPORT 0001393905-25-000118 001-42389 25744145 34 24186
2025-03-06 6-K REPORT 0001393905-25-000095 001-42389 25714871 34 22990
2025-03-04 6-K REPORT 0001393905-25-000085 001-42389 25702836 34 29270
2025-02-18 6-K REPORT 0001393905-25-000067 001-42389 25634055 34 25716
2025-02-14 6-K REPORT 0001393905-25-000063 001-42389 25626353 34 24670
2025-02-12 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001877291-25-000003 005-94858 25616177 34 5780
2025-02-12 6-K REPORT 0001393905-25-000056 001-42389 25614507 34 24391
2025-02-11 6-K REPORT 0001393905-25-000054 001-42389 25607243 34 19659
2025-01-23 6-K REPORT 0001393905-25-000028 001-42389 25549467 34 61975
2025-01-22 6-K REPORT 0001393905-25-000026 001-42389 25545475 34 53222
2025-01-08 6-K REPORT 0001393905-25-000011 001-42389 25518090 34 34364
2024-12-11 6-K REPORT 0001393905-24-000417 001-42389 241541192 34 39919
2024-11-26 6-K REPORT 0001393905-24-000403 001-42389 241497412 34 133258
2024-11-25 6-K REPORT 0001393905-24-000401 001-42389 241497174 34 114349
2024-11-25 6-K REPORT 0001393905-24-000399 001-42389 241496870 34 472982
2024-11-21 6-K REPORT 0001393905-24-000395 001-42389 241485473 34 24285
2024-11-19 6-K REPORT 0001393905-24-000393 001-42389 241472775 34 24599
2024-11-18 6-K REPORT 0001393905-24-000391 001-42389 241469353 34 31964
2024-11-12 6-K REPORT 0001393905-24-000385 001-42389 241447342 34 24503
2024-11-08 CERT 8A_Cert_BHST.pdf 0001354457-24-000857 001-42389 241441521 34 245050
2024-11-08 CERT BHST_8A_Cert.pdf 0001354457-24-000856 001-42389 241441012 34 247886
2024-11-08 6-K REPORT 0001393905-24-000380 001-42389 241438410 34 41995
2024-10-29 6-K REPORT 0001393905-24-000365 001-42389 241402191 34 42427
2024-10-28 6-K REPORT 0001393905-24-000363 001-42389 241400989 34 33178
2024-10-28 8-A12B REGISTRATION STATEMENT 0001393905-24-000361 001-42389 241400041 34 17544
2024-10-23 6-K REPORT 0001393905-24-000359 000-56663 241389578 34 173366
2024-10-16 6-K REPORT 0001393905-24-000354 000-56663 241374140 34 24748
2024-09-20 6-K REPORT 0001393905-24-000339 000-56663 241314217 34 20600
2024-09-20 6-K REPORT 0001393905-24-000335 000-56663 241312617 34 32934
2024-09-12 6-K REPORT 0001393905-24-000327 000-56663 241294857 34 23122
2024-09-06 6-K REPORT 0001393905-24-000322 000-56663 241284336 34 52186
2024-09-05 6-K REPORT 0001393905-24-000318 000-56663 241278989 34 23265
2024-08-29 6-K REPORT 0001393905-24-000310 000-56663 241264126 34 168743
2024-08-29 6-K REPORT 0001393905-24-000306 000-56663 241262414 34 460575
2024-08-27 SEC STAFF LETTER filename1.pdf 9999999997-24-003646 134857
2024-08-27 UPLOAD filename1.pdf 0000000000-24-009738 000-56663 39893
2024-08-22 20FR12G/A REGISTRATION STATEMENT 0001393905-24-000304 000-56663 241231593 34 2034913
2024-08-21 UPLOAD filename1.pdf 0000000000-24-009566 000-56663 42443
2024-08-14 20FR12G/A REGISTRATION STATEMENT 0001393905-24-000290 000-56663 241207710 34 2140577
2024-08-06 UPLOAD filename1.pdf 0000000000-24-008980 000-56663 45068
2024-07-24 20FR12G/A REGISTRATION STATEMENT 0001393905-24-000268 000-56663 241138010 34 7371609
2024-07-12 SEC STAFF LETTER filename1.pdf 9999999997-24-003212 141540
2024-07-10 UPLOAD filename1.pdf 0000000000-24-007803 000-56663 57983
2024-06-14 20FR12G REGISTRATION STATEMENT 0001393905-24-000225 000-56663 241045597 34 9920048
2024-01-11 D xslFormDX01/primary_doc.xml 06b 0001814587-24-000001 021-502184 24528881 33 12434
2023-11-21 D xslFormDX01/primary_doc.xml 06b 0001814587-23-000004 021-497891 231428667 33 12534
2023-08-10 D xslFormDX01/primary_doc.xml 06b 0001534122-23-000008 021-489365 231158843 33 12525
2022-10-25 D xslFormDX01/primary_doc.xml 06b 0001534122-22-000024 021-462770 221329653 33 12533
2021-09-13 D xslFormDX01/primary_doc.xml 06b 0001534122-21-000016 021-413136 211249365 33 11673
2021-02-17 D xslFormDX01/primary_doc.xml 06b 0001534122-21-000003 021-389722 21644855 33 11672
2020-09-29 D xslFormDX01/primary_doc.xml 06b 0001534122-20-000016 021-376541 201205505 33 11444
2020-08-13 D xslFormDX01/primary_doc.xml 06b 0001534122-20-000015 021-373194 201099097 33 11441
2020-04-21 D xslFormDX01/primary_doc.xml 06b 0001534122-20-000008 021-365447 20804618 33 10535
2019-10-08 D xslFormDX01/primary_doc.xml 06b 0001534122-19-000033 021-350596 191142474 33 10804
2018-10-15 D/A xslFormDX01/primary_doc.xml 06b 0001534122-18-000030 021-323532 181121767 33 9394
2018-10-15 D xslFormDX01/primary_doc.xml 06b 0001534122-18-000029 021-323532 181121727 33 9284
2017-11-24 D xslFormDX01/primary_doc.xml 06b 0001534122-17-000035 021-299449 171221323 33 8189

Latest XBRL company facts

One latest value per concept from companyfacts (101 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 22.67M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment USD 1.04M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets AdditionsOtherThanThroughBusinessCombinationsRightofuseAssets USD 399,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full Assets Assets USD 47.66M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full CashAndCashEquivalents CashAndCashEquivalents USD 23.02M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full DisposalsPropertyPlantAndEquipment DisposalsPropertyPlantAndEquipment USD 431,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full GeneralAndAdministrativeExpense GeneralAndAdministrativeExpense USD 4.93M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full GrossProfit GrossProfit USD 20.48M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full IncreaseDecreaseInRightofuseAssets IncreaseDecreaseInRightofuseAssets USD -85,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full IncreaseDecreaseThroughOtherChangesRightofuseAssets IncreaseDecreaseThroughOtherChangesRightofuseAssets USD 228,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full InterestExpenseOnOtherFinancialLiabilities InterestExpenseOnOtherFinancialLiabilities USD 5.54M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full InterestIncomeOnDeposits InterestIncomeOnDeposits USD 0 2024-01-01 2024-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full InterestIncomeOnOtherFinancialAssets InterestIncomeOnOtherFinancialAssets USD 0 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
ifrs-full LeaseLiabilities LeaseLiabilities USD 1.41M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full ProceedsFromIssuingOtherEquityInstruments ProceedsFromIssuingOtherEquityInstruments USD 0 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full ProfitLoss ProfitLoss USD -11.13M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full ResearchAndDevelopmentExpense ResearchAndDevelopmentExpense USD 5.31M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full RightofuseAssets RightofuseAssets USD 8.41M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
ifrs-full SellingExpense SellingExpense USD 15.81M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AccountsPayableAndAccruedLiabilitiesCurrent Accounts Payable and Accrued Liabilities, Current USD 2.17M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.63M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 1.98M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 386,000 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 2.18M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 133.00M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 601,000 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AssetsCurrent Assets, Current USD 30.50M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap AssetsNoncurrent Assets, Noncurrent USD 17.16M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 23.02M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 23.02M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 20.60M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations USD 39,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted shares 2.94M 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap ConvertibleDebtCurrent Convertible Debt, Current USD 0 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap CostOfRevenue Cost of Revenue USD 14.03M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount USD 7.60M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap DeferredIncome Deferred Income USD 492,000 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 1.62M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap DerivativeLiabilitiesCurrent Derivative Liability, Current USD 0 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.6 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap EmployeeBenefitsAndShareBasedCompensationNoncash Employee Benefit and Share-based Payment Arrangement, Noncash USD 597,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 10.13M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -11.06M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 39,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -76,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 865,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD -415,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD 904,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncreaseDecreaseInOtherAccruedLiabilities Increase (Decrease) in Other Accrued Liabilities USD 482,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD 240,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 0 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap InventoryNet Inventory, Net USD 4.56M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 47.66M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap LiabilitiesCurrent Liabilities, Current USD 7.68M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 14.53M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 30.19M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -2.37M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -7.23M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -11.13M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest USD -12.91M 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap NotesAndLoansReceivableNetCurrent Financing Receivable, after Allowance for Credit Loss, Current USD 935,000 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap NumberOfOperatingSegments Number of Operating Segments pure 2 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap OperatingExpenses Operating Expenses USD 26.05M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -5.58M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 8.41M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 1.16M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 452,000 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 1.98M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 5.54M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 54,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OtherSignificantNoncashTransactionValueOfConsiderationGiven1 Other Significant Noncash Transaction, Value of Consideration Given USD 399,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap OtherSignificantNoncashTransactionValueOfConsiderationReceived1 Other Significant Noncash Transaction, Value of Consideration Received USD 0 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 2.35M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 18.26M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap ProceedsFromOtherDebt Proceeds from Other Debt USD 0 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap ProceedsFromRepaymentsOfOtherDebt Proceeds from (Repayments of) Other Debt USD 12.40M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 36,000 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 6.80M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 10.51M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 8.33M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap ReclassificationsOfTemporaryToPermanentEquity Reclassifications of Temporary to Permanent Equity USD 934,000 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap RepaymentsOfConvertibleDebt Repayments of Convertible Debt USD 0 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap RepaymentsOfOtherDebt Repayments of Other Debt USD 1.38M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap RestrictedCash Restricted Cash USD 433,000 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -107.55M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap Revenues Revenues USD 34.51M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap SharesOutstanding Shares, Outstanding shares 17.33M 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap ShortTermBorrowings Short-term Debt USD 149,000 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap StockGrantedDuringPeriodValueSharebasedCompensation Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture USD 601,000 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 25.45M 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 1.33M 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 603,904 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 106,132 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments USD 20.53M 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 16,000 2023-01-01 2023-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 4.33M 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodValueOther Stock Issued During Period, Value, Other USD 2.30M 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 408,000 2024-01-01 2024-12-31 2024 FY 40-F 2025-03-31 0001376474-25-000299
us-gaap WeightedAverageNumberOfSharesIssuedBasic Weighted Average Number of Shares Issued, Basic shares 18.41M 2025-01-01 2025-12-31 2025 FY 40-F 2026-03-31 0001376474-26-000257

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →